These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 19361440)

  • 1. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
    Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
    J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
    Chrencik JE; Patny A; Leung IK; Korniski B; Emmons TL; Hall T; Weinberg RA; Gormley JA; Williams JM; Day JE; Hirsch JL; Kiefer JR; Leone JW; Fischer HD; Sommers CD; Huang HC; Jacobsen EJ; Tenbrink RE; Tomasselli AG; Benson TE
    J Mol Biol; 2010 Jul; 400(3):413-33. PubMed ID: 20478313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
    Rashid S; Bibi N; Parveen Z; Shafique S
    J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.
    Lucet IS; Fantino E; Styles M; Bamert R; Patel O; Broughton SE; Walter M; Burns CJ; Treutlein H; Wilks AF; Rossjohn J
    Blood; 2006 Jan; 107(1):176-83. PubMed ID: 16174768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational analyses of JAK1 kinase domain: subtle changes in the catalytic cleft influence inhibitor specificity.
    Zhang X; Hu Y; Yuan Z
    Biochem Biophys Res Commun; 2008 May; 370(1):72-6. PubMed ID: 18346458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the discovery of selective JAK inhibitors.
    Menet CJ; Rompaey LV; Geney R
    Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
    Vainchenker W; Dusa A; Constantinescu SN
    Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain.
    Hall T; Emmons TL; Chrencik JE; Gormley JA; Weinberg RA; Leone JW; Hirsch JL; Saabye MJ; Schindler JF; Day JE; Williams JM; Kiefer JR; Lightle SA; Harris MS; Guru S; Fischer HD; Tomasselli AG
    Protein Expr Purif; 2010 Jan; 69(1):54-63. PubMed ID: 19781647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
    Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A
    Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK pathway induction of c-Myc critical to IL-5 stimulation of cell proliferation and inhibition of apoptosis.
    Lee WH; Liu FH; Lin JY; Huang SY; Lin H; Liao WJ; Huang HM
    J Cell Biochem; 2009 Apr; 106(5):929-36. PubMed ID: 19180571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective JAK inhibitors.
    Dymock BW; Yang EG; Chu-Farseeva Y; Yao L
    Future Med Chem; 2014; 6(12):1439-71. PubMed ID: 25329199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
    Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R
    J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
    Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
    J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK1 N-terminus binds to conserved Box 1 and Box 2 motifs of cytokine receptor common beta subunit but signal activation requires JAK1 C-terminus.
    Huang HM; Lee YL; Chang TW
    J Cell Biochem; 2006 Nov; 99(4):1078-84. PubMed ID: 16767694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of human Fyn kinase domain complexed with staurosporine.
    Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
    Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
    Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.